MedTrace Logo

Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies

NCT04601181 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-12-01

No results posted yet for this study

Summary

This is a single-center, nonrandomized, open-label, study to evaluate the safety and clinical activity of allogeneic CAR-T targeting CD22 in patients with refractory or relapsed CD22-positive B cell malignancies

Conditions

  • B Cell Malignancy

Interventions

BIOLOGICAL

ThisCART22 cells injection

Assigned Interventions Biological/Vaccine: ThisCART22 cells 0.2-60 x 10\^6 CAR-T cells per kg body weight. Intervention study

Sponsors & Collaborators

  • The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

    collaborator UNKNOWN

  • Fundamenta Therapeutics, Ltd.

    lead INDUSTRY

Principal Investigators

  • Xingbing Wang, M.D. · The First Affiliated Hospital of USTC (Anhui Provincial Hospital)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-23
Primary Completion
2022-10-15
Completion
2023-10-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04601181 on ClinicalTrials.gov